Find drugs by alphabetical list:
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z View All
Last updated on: Jan 24, 2007
Brand Name: | Infasurf |
Active Ingredient: | calfactant |
Strength(s): | 35mg of phospholipid/ml |
Dosage Form(s): | Intratracheal suspension |
Company Name: | ONY, Inc. |
Availability: | Prescription only, for professional use only |
*Date Approved by the FDA: | July 1, 1998 |
*Approval by FDA does not mean that the drug is available for consumers at this time.
This information is provided by the U.S. Food & Drug Administration.
For more information about this drug, click here.
|
Infasurf is used to prevent the development of Respiratory Distress Syndrome (RDS) in premature babies considered at high risk for RDS and to treat or "rescue" premature babies with RDS.
Infasurf is an extract of a natural substance (surfactant) necessary for effective breathing. Babies with RDS or at high risk of developing RDS are lacking in this substance.
General Precautions with Infasurf:
Treatment with Infasurf is not a substitute for intensive care. Infasurf should only be given by health care professionals experienced in treating premature babies at risk of RDS or with RDS.
What are some possible side effects of Infasurf?
Infasurf is given to babies within several hours of birth by medical professionals in a hospital who will monitor the baby for any negative reactions.
This information is provided by the U.S. Food & Drug Administration.
For more information about this drug, click here.
Accupril
Actonel
Actos
Allegra
Altace
Atenolol
Avandia
Celebrex
Celexa
Cialis
Coreg
Cozaar
Crestor
Diovan
Effexor
Evista
Flomax
Fluoxetine
Fosamax
Glucophage
Latisse
Levitra
Levoxyl
Lexapro
Lipitor
Lisinopril
Metformin
Neurontin
Nexium
Norvasc
Paxil
Plavix
Pravachol
Premarin
Prevacid
Prilosec
Propecia
Protonix
Prozac
Seroquel
Simvastatin
Singulair
Toprol-XL
Viagra
Zetia
Zithromax
Zocor
Zoloft
Zyprexa
Zyrtec